Quality of life in the trastuzumab for gastric cancer trial

Oncologist

Volumn 19, Issue 7, 2014, Pages 712-719

  Satoh, Taroh ^a   Bang, Yung Jue ^b   Gotovkin, Evgeny A ^c   Hamamoto, Yasuo ^d   Kang, Yoon Koo ^e   Moiseyenko, Vladimir M ^f   Ohtsu, Atsushi ^g   Van Cutsem, Eric ^h   Al Sakaff, Nedal ⁱ   Urspruch, Alexa ⁱ   Hill, Julie ^j   Weber, Harald A ⁱ   Chung, Hyun Cheol ^k  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Seoul National University College of Medicine   (South Korea)

^c Ivanovo TB Dispensary   (Russian Federation)

^d TOCHIGI CANCER CENTER   (Japan)

^e University of Ulsan College of Medicine   (South Korea)

^f N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j Roche Products   (Australia)

^k Yonsei University College of Medicine   (South Korea)

more..

Author keywords

Chemotherapy; Gastric cancer; HER2; Quality of life; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSPHAGIA; DYSPNEA; FATIGUE; HAIR LOSS; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; PAIN ASSESSMENT; PATIENT ATTITUDE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH CANCER; TASTE DISORDER; VISUAL ANALOG SCALE; XEROSTOMIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84903631229     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0058     Document Type: Article

References (27)

1. GLOBOCAN stomach cancer fact sheet 2012. Available at http://globocan.iarc.fr/old/FactSheets/ cancers/stomach-new.asp. AccessedMay 23, 2014.
2. Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: Is there a global standard? Curr Treat Options Oncol 2011;12: 96-106.
3. Rüschoff J, HannaW, BilousMet al. HER2 testing in gastric cancer: A practical approach. Mod Pathol 2012;25:637-650.
4. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011;18:53-59.
5. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51.
7. Bezjak A, Ng P, Skeel R et al. Oncologists' use of quality of life information: Results of a survey of Eastern Cooperative Oncology Group physicians. Qual Life Res 2001;10:1-13.
8. Gelber S, Gelber RD, Cole BF et al. The Q-TWiST Method. Quality of Life Newsletter 1996;16:3-4.
9. Revicki DA, Feeny D, Hunt TL et al. Analyzing oncology clinical trial data using the Q-TWiST method: Clinical importance and sources for health state preference data. Qual Life Res 2006;15: 411-423.
10. Vickery CW, Blazeby JM, Conroy T et al. Development of an EORTC disease-specific quality of lifemodule for use in patients with gastric cancer. Eur J Cancer 2001;37:966-971.
11. Blazeby JM, Conroy T, Bottomley A et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004;40:2260-2268.
12. AaronsonNK, Ahmedzai S, BergmanBet al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
13. Huskisson EC. Measurement of pain. Lancet 1974;2:1127-1131.
14. Fayers PM, Aaronson NK, Bjordal K et al. The EORTC QLC-C30 Scoring Manual (3rd Edition). Brussels: EORTC, 2001.
15. Tengs TO, Wallace A. One thousand healthrelated quality-of-life estimates. Med Care 2000;38: 583-637.
16. Xie F, O'Reilly D, Ferrusi IL et al. Illustrating economic evaluation of diagnostic technologies: Comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol 2009;6:317-323.
17. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144.
18. Shen L, Kang YK, Lichinitser M et al. Healthrelated quality of life in patients with HER2-positive advanced gastric or gastroesophageal junction cancerwithhighHER2expressionlevels-exploratory analysis ofthephaseIIIToGAStudy. Eur JCancer2011; 47:S231-S232.
19. Osoba D, Slamon DJ, Burchmore M et al. Effects on quality of life of combined trastuzumab andchemotherapy inwomenwithmetastaticbreast cancer. J Clin Oncol 2002;20:3106-3113.
20. Ajani JA, Moiseyenko VM, Tjulandin S et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3210-3216.
21. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19: 1450-1457.
22. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trialcomparingmitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU)with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
23. Curran D, Pozzo C, Zaluski J et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: Results of a randomised phase III trial. Qual Life Res 2009;18:853-861.
24. Al-Batran SE, Ajani JA. Impact ofchemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010;116:2511-2518.
25. Funaioli C, Longobardi C, Martoni AA. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: A review of phase III trials. J Chemother 2008;20:14-27.
26. Sherrill B, Di Leo A, AmonkarMMet al. Qualityof-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. CurrMedRes Opin 2010;26:767-775.
27. Ohtsu A, Wang L, Lim H et al. Quality of life results from a phase III study of trastuzumab plus chemotherapy as first-line therapy in patients with HER2-positive advanced gastric and gastroesophageal junction cancer. Ann Oncol 2010;21 (suppl 6):O-0011.